

Title: List of Accredited Methods (Flexible Scope Category II)		Page 1 of 12	
Doc. #:	QML 402-2e	Revision:	002

Status: 25.06.2021

Precision for Medicine GmbH

FLEXIBLE SCOPE OF ACCREDITATION CATEGORY II
(DIN EN/ISO 17025:2018)

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu FoxP3 (Tregs)/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD3+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyclor 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CCR6+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03, QMA 510-4e_Rev00	hu GNLY+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu NK Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu B Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu neutrophile Granulocytes/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu naive CD8-T+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_7e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev01 Rev02, QMA 510-3e_Rev03, QMA 510-4e_Rev00	hu Th17 Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD4 Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_15e_Rev01, QMA 504-2_22e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD8 Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu TFH Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Monocytes / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Eosinophils/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Basophils / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu monocytic MDSC Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu PD1 + Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu non-classical Monocytes/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu pDC+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CXCR3+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu LAG3+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu memory B Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu S1PR1+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CCR7+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu ITGA4+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu PTGFRB+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CRTH2+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu S1PR5+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu GATA3+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Doc. #: QML 402-2e

Revision: 002

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu COL1A1/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu memCD4/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu naive B Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche
QMA 504-2_8e Annex1_Rev01, QMA 504-5e_Rev06, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 510-2e_Rev02, QMA 504-2_24e_Rev01, QMA 506-2e_Rev00, QMA 506-3e_Rev02	E gene/ quantitative RT-PCR	Human Suspension Cells (incl. Body Fluids)	Light Cycler 480 Roche

Doc. #: QML 402-2e	Revision: 002
---------------------------	----------------------

Status: 25.06.2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu IL6R+ cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu TIGIT+ cells/ quantitative RT-PCR	Human Tissue and Suspension Cells (incl. Body Fluids)	Light Cyler 480 Roche

Abbreviations used:

- DIN Deutsches Institut für Normung e.V.
- EN European Standard
- FFPE Formalin-fixed, Paraffin-embedded
- hu human
- ISO International Organization for Standardization
- RT-PCR Real-Time Polymerase Chain Reaction
- IEC International Electrotechnical Commission